BR112023020805A2 - Compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes - Google Patents

Compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes

Info

Publication number
BR112023020805A2
BR112023020805A2 BR112023020805A BR112023020805A BR112023020805A2 BR 112023020805 A2 BR112023020805 A2 BR 112023020805A2 BR 112023020805 A BR112023020805 A BR 112023020805A BR 112023020805 A BR112023020805 A BR 112023020805A BR 112023020805 A2 BR112023020805 A2 BR 112023020805A2
Authority
BR
Brazil
Prior art keywords
oxadiazole
histone deacetylase
inhibitor
pharmaceutical composition
thiocarbonyl compounds
Prior art date
Application number
BR112023020805A
Other languages
English (en)
Inventor
Hyunjin Michael Kim
Chang Sik Lee
Jung Taek Oh
Song Hyeseung
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of BR112023020805A2 publication Critical patent/BR112023020805A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes. apresenta invenção que se refere a um novo composto de 1,3,4-oxadiazol tiocarbonil com uma atividade inibitória de histona desacetilase 6 (hdac6), estereoisômeros deste, sais farmaceuticamente aceitáveis deste, um uso deste para a preparação de um medicamento, uma composição farmacêutica contendo-o, um método terapêutico usando a composição, e um método de preparação deste, em que um novo composto com uma atividade inibitória seletiva de hdac6 é representado pela fórmula i. [fórmula i]
BR112023020805A 2021-04-08 2022-04-07 Compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes BR112023020805A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210046134A KR20220139752A (ko) 2021-04-08 2021-04-08 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물
PCT/IB2022/053253 WO2022215020A1 (en) 2021-04-08 2022-04-07 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
BR112023020805A2 true BR112023020805A2 (pt) 2023-12-12

Family

ID=83546041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020805A BR112023020805A2 (pt) 2021-04-08 2022-04-07 Compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes

Country Status (8)

Country Link
EP (1) EP4288419A1 (pt)
JP (1) JP2024516122A (pt)
KR (1) KR20220139752A (pt)
CN (1) CN117120421A (pt)
BR (1) BR112023020805A2 (pt)
CA (1) CA3211625A1 (pt)
TW (1) TW202239756A (pt)
WO (1) WO2022215020A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2762505B2 (ja) * 1989-01-14 1998-06-04 日産化学工業株式会社 縮合ヘテロ環誘導体、その製法及び除草剤
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
PT2526093T (pt) 2010-01-22 2016-11-25 Acetylon Pharmaceuticals Inc Compostos amida reversa como inibidores de proteína desacetilase e métodos de utilização dos mesmos
AU2013230881A1 (en) 2012-03-07 2014-10-30 Board Of Trustees Of The University Of Illinois Selective histone deactylase 6 inhibitors
RU2700696C2 (ru) * 2015-07-27 2019-09-19 Чонг Кун Данг Фармасьютикал Корп. 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JP7470058B2 (ja) * 2019-01-30 2024-04-17 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
WO2022215020A1 (en) 2022-10-13
TW202239756A (zh) 2022-10-16
AU2022253373A1 (en) 2023-09-28
CA3211625A1 (en) 2022-10-13
EP4288419A1 (en) 2023-12-13
JP2024516122A (ja) 2024-04-12
KR20220139752A (ko) 2022-10-17
CN117120421A (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112023003832A2 (pt) Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos
BR112018001720A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112023000560A2 (pt) Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
ECSP099706A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BRPI1008727B8 (pt) derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson
BR112023020805A2 (pt) Compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
BR112022006279A2 (pt) Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
AR078126A1 (es) Antagonistas de glicina b, composiciones farmaceuticas, usos y proceso de preparacion de los mismos
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
BR112023002082A2 (pt) Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
BR112022016761A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112022016743A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112022005729A2 (pt) Compostos de pirazolopiridina como inibidores seletivos da quinase de btk
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
CL2022000320A1 (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones
BR112023003744A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2